The Neuroprotective Effect of @entity19316 Against Contusive @entity1566 by Activating @entity6229 in XXXX .

@entity19316 @entity6229 @entity8312 @entity1566 @entity35
@entity19316 ( @entity8312 ) has been suggested to have neuroprotective effects against @entity1566 ( @entity1566 ); however, few studies have examined these effects and the corresponding mechanism. Therefore, the present study aimed to investigate the neuroprotective effect and underlying mechanism of @entity8312 against contusive @entity1566 . Adult male @entity35 were randomly divided into Sham, normal saline (NS) and @entity8312 groups. Each group was divided into subgroups according to the time of sacrifice: 1, 3, 7, 14, 21 and 28  days post-injury. Laminectomy was performed in all groups, followed by contusive @entity1566 establishment in the @entity8312 and NS groups. @entity8312 (80  mg/kg) was injected thereafter daily from 3 to 7  days post-injury in the @entity8312 group, which was replaced by equal volume of normal saline in the NS group. The Basso-Beattie-Bresnahan (BBB) Locomotor Rating Scale was measured at different time points post-injury to appraise locomotor functional recovery. Quantitative real-time PCR and immunofluorescence were used to assess the spatio-temporal expression of peroxisome proliferator-activated receptor-y coactivator-1a ( @entity6229 ), while western blot was adopted to detect the effect of @entity8312 on @entity6229 . Neural apoptotic changes and neuronal survival were evaluated using the TUNEL method and Nissl staining, respectively. @entity8312 treatment markedly increased @entity6229 expression, neuronal survival and BBB locomotor scores, while also reducing neural apoptosis. These results demonstrate that @entity8312 is neuroprotective against contusive @entity1566 , with the inhibition of neural apoptosis and increase of neuronal survival. The sustained expression of @entity6229 may partially contribute to the @entity8312 -mediated neuroprotective effect.
